Abstract: The invention relates to a process for the preparation of granules comprising an oily substance. It relates also to granules for a pharmaceutical formulation and to a tablet as a product of further processing.

Abstract: The invention relates to a salt of an ACE inhibitor dicarboxylic acid with an organic amine and/or an alkali compound, a transdermal therapeutic system comprising the salt, and a method of producing the transdermal therapeutic system.

Abstract: The invention relates to a pharmaceutical active-ingredient-containing formulation for oral administration which is coated with a single coating of a film-forming polymer, the coating comprising a mixture of at least two separating agents and no stabilizer.

Abstract: Film-form, single-layered, cavity-free preparation free of surfactants, effervescent additive and taste masker and comprising one or more film former(s), one or more gel former(s) and one or more active ingredient(s) from the group of anti-emetics and anti-migraine agents.

Abstract: Film-form, single-layered, cavity-free preparation free of surfactants, effervescent additive and taste masker and comprising one or more film former(s), one or more gel former(s) and one or more active ingredient(s) from the group of neuroleptics.

Abstract: The invention relates to a process for the preparation of granules comprising an oily substance. It relates also to granules for a pharmaceutical formulation and to a tablet as a product of further processing.

Abstract: The invention relates to a transdermal therapeutic system comprising a surface layer which is impervious with respect to an active ingredient; a self-adherent matrix layer or a plurality of matrix layers, wherein the exposed matrix layer is, at least self-adherent when the system is applied. Said system also comrises a pull-off protective coating, whereby the matrix layer(s) contains one or more active ingredients and/or one or more biologically active substances and highly dispersed silicon dioxide. Said system contains silicon dioxide in order to increase skin permeation.

Abstract: The invention relates to a matrix-controlled transdermal therapeutic system comprising (i) an active-ingredient-impermeable cover layer, (ii) a self-adhesive matrix layer, or a plurality of matrix layers of which at least the matrix layer exposed while applying the system is self-adhesive, or one or more matrix layers whose surface remote from the cover layer and intended for adhesion at the application site is coated with an adhesive, the matrix layers comprising at least one ACE inhibitor (angiotensin converting enzyme inhibitor), the metabolite of which is a dicarboxylic acid and which is selected from the following group:

Abstract: The invention relates to a pharmaceutical preparation which consists of or contains cyclosporin A, an emulsifying &agr;-tocopherol derivative, an ethoxylation product of vegetable oils, fatty acids or fats as a further emulsifier and a pharmaceutically customary alcohol.

Abstract: A transdermal patch contains an active loratidine metabolite contained with polyacrylate polymer matrix. The transdermal patch provides pharmaceutically useful transdermal flux rates over time.

Abstract: The invention relates to a transdermal system containing at least one angiotensin-converting enzyme inhibitor.

Abstract: Pharmaceutical compositions containing enolic carboxamide type antiinflammatory agent meloxicam that exhibit improved wettability, aqueous solubility, dissolution behaviour over a broad range of pH, and that are prepared by crystal structure modification of the drug through dry or wet mechanical homogenization with two further components—one of them is selected from a group of oligo—and dissolution improving, or alkalizing agent. The application of the formulations according to the present invention results in an improved biovailability and effectiveness of meloxicam.

Abstract: The invention relates to a pharmaceutical preparation which consists of or contains cyclosporin A, an emulsifying &agr;-tocopherol derivative, an ethoxylation product of vegetable oils, fatty acids or fats as a further emulsifier and a pharmaceutically customary alcohol.

Abstract: The invention relates to a pharmaceutical preparation which comprises or consists of the following components: (i) an initial dose of active ingredient, which is provided by the active ingredient together with optional excipients, (ii) a first delayed-release type of pellet, in which the active ingredient and optional excipients are covered with a coating, and (iii) a second delayed-release type of pellet, in which the active ingredient and optional excipients are again covered with a coating, wherein the active ingredient is an ACE inhibitor, and wherein the amounts of the coatings according to (ii) and (iii) are present in a ratio, based on weight, within the range of from 1:2 to 1:7.

Abstract: A pharmaceutical formulation comprising a benzimidazole derivative as active ingredient, and as excipients, at least one cyclodextrin and at least one amino acid.

Abstract: Non-deliquescent formulation comprising or consisting of sodium valproate and cyclodextrin having a molar ratio of sodium valproate to cyclodextrin within the range of from 1:0.01 to 1:0.09.

Abstract: A transdermal patch contains an active loratidine metabolite contained with a polyacrylate polymer matrix. The transdermal patch provides pharmaceutically useful transdermal flux rates over time.